Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
p53 synthetic long peptides vaccine with cyclophosphamide for ovarian cancer
2007-007734-19Phase 2Completed
- Sponsor
- University Medical Center Groningen
- Start
- Jan 2008
- Modality
- Vaccines & Immunotherapeutics, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of p53 synthetic long peptide vaccine in ovarian cancer, sponsored by University Medical Center Groningen. Primary endpoint: Clinical response assessed by CA-125 and CT-scan. Started Jan 2008; status: completed.
02
Drugs
p53 synthetic long peptide vaccine
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on 2007-007734-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-007734-19.